These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 23885825)

  • 1. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
    Vasilakos JP; Tomai MA
    Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants.
    Dowling DJ
    Immunohorizons; 2018 Jul; 2(6):185-197. PubMed ID: 31022686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New perspective in immunotherapy: local imiquimod treatment].
    Kemény L; Nagy N
    Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice.
    Zhang WW; Matlashewski G
    Infect Immun; 2008 Aug; 76(8):3777-83. PubMed ID: 18474642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the neuroinflammatory response to TLR7 stimulation in the brain: comparison of multiple TLR7 and/or TLR8 agonists.
    Butchi NB; Pourciau S; Du M; Morgan TW; Peterson KE
    J Immunol; 2008 Jun; 180(11):7604-12. PubMed ID: 18490763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR7 and TLR8 as targets in cancer therapy.
    Schön MP; Schön M
    Oncogene; 2008 Jan; 27(2):190-9. PubMed ID: 18176600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants.
    Smith AJ; Li Y; Bazin HG; St-Jean JR; Larocque D; Evans JT; Baldridge JR
    Vaccine; 2016 Aug; 34(36):4304-12. PubMed ID: 27402566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antiviral activity of Toll-like receptor 7 and 7/8 agonists.
    Miller RL; Meng TC; Tomai MA
    Drug News Perspect; 2008 Mar; 21(2):69-87. PubMed ID: 18389099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation.
    Hackstein H; Knoche A; Nockher A; Poeling J; Kubin T; Jurk M; Vollmer J; Bein G
    Cell Immunol; 2011; 271(2):401-12. PubMed ID: 21889130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.
    Fahey LM; Raff AB; Da Silva DM; Kast WM
    J Immunol; 2009 Mar; 182(5):2919-28. PubMed ID: 19234187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial Watch: experimental TLR7/TLR8 agonists for oncological indications.
    Frega G; Wu Q; Le Naour J; Vacchelli E; Galluzzi L; Kroemer G; Kepp O
    Oncoimmunology; 2020 Jul; 9(1):1796002. PubMed ID: 32934889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod.
    Othoro C; Johnston D; Lee R; Soverow J; Bystryn JC; Nardin E
    Infect Immun; 2009 Feb; 77(2):739-48. PubMed ID: 19047411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
    Hunt JR; Kleindl PA; Moulder KR; Prisinzano TE; Forrest ML
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126788. PubMed ID: 31784317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
    Rostamian M; Niknam HM
    Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
    Fehres CM; Bruijns SC; van Beelen AJ; Kalay H; Ambrosini M; Hooijberg E; Unger WW; de Gruijl TD; van Kooyk Y
    Eur J Immunol; 2014 Aug; 44(8):2415-24. PubMed ID: 24825342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
    Smits EL; Ponsaerts P; Berneman ZN; Van Tendeloo VF
    Oncologist; 2008 Aug; 13(8):859-75. PubMed ID: 18701762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.
    Johnson TR; Rao S; Seder RA; Chen M; Graham BS
    Vaccine; 2009 May; 27(23):3045-52. PubMed ID: 19428918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, purification, and characterization of oligoribonucleotides that act as agonists of TLR7 and/or TLR8.
    Lan T; Kandimalla ER
    Methods Mol Biol; 2011; 764():249-61. PubMed ID: 21748646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity.
    Short KK; Miller SM; Walsh L; Cybulski V; Bazin H; Evans JT; Burkhart D
    J Control Release; 2019 Dec; 315():186-196. PubMed ID: 31654684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides.
    Gorden KK; Qiu XX; Binsfeld CC; Vasilakos JP; Alkan SS
    J Immunol; 2006 Nov; 177(10):6584-7. PubMed ID: 17082568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.